Evolving Considerations in the Individualization of Treatment in Metastatic Colorectal Cancer (mCRC)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 10, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Bayer HealthCare Pharmaceuticals, Merck & Company, and Taiho Oncology Inc.

Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. Colorectal cancer, when discovered early, is highly treatable however once the disease has spread, or metastasized, treatment and management become much more difficult. Metastatic colorectal cancer (mCRC) carries a poor prognosis, with a 5-year survival rate of approximately 70% for regional metastases and 13% for distant metastases. The prognosis of patients with mCRC has significantly improved in recent years with the introduction of individualized or target therapies such as inhibitors of the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. Traditional regimens such as chemotherapy may also be used in combination with targeted therapies, further increasing efficacy and ultimately improving patient survival and quality of life.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast the safety and efficacy of VEGF- and EGFR-targeted agents in the treatment of mCRC

  • Evaluate the relative benefits and limitations of current therapy for mCRC beyond second-line therapy

  • Demonstrate the ability to manage potential challenges in later lines of therapy in mCRC

  • Describe the role of molecular biomarkers in selecting appropriate targeted agents for patients with mCRC in the clinical setting, as well as the roles of additional patient-driven factors, such as age, gender, and HRQOL

  • Integrate clinical data and guideline recommendations into decisions about the optimal use of VEGF and EGFR-directed therapy in treatment protocols for patients with mCRC

  • Define the risks and adverse events associated with the VEGF- and EGFR-targeted agents indicated for the treatment of patients with mCRC in order to maximize tolerability and adherence to therapeutic regimens

Faculty: Minsig Choi, MD
Director of Outpatient Oncology
Co-leader Colorectal MDT
Associate Professor of Medicine
Stony Brook University


Dr. Choi serves on the speakers bureau for Bayer, Celgene and Novartis. This presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Association of Managed Care Nurses (AAMCN) and the National Association of Managed Care Physicians (NAMCP). NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Bayer HealthCare Pharmaceuticals, Merck & Company, and Taiho Oncology Inc.

NAMCP and/or this website do not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health-related concern, consult with your physician or healthcare professional.

Click Here To Continue